BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer


2/10/2011 7:24:03 AM

MENLO PARK, Calif., Feb. 10, 2011 /PRNewswire/ -- 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business Officer.

(Logo: http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

"Steve's contributions have been pivotal as a member of the team during his tenure at 3-V," said Merdad V. Parsey, MD, PhD, 3-V's Chief Executive Officer. "I look forward to working with him as we continue to build the 3-V team and advance the company's programs."

Mr. Brady joined the 3-V team in 2010 as Vice President, Corporate Development, Strategy & Operations, with management responsibility for the company's business functions, including strategy, finance and legal. Prior to joining the company, Mr. Brady was the Vice President of Corporate Development of Proteolix, Inc. where he had primary responsibility for Proteolix's business development activities, resulting in the sale of the company to Onyx Pharmaceuticals, Inc. Previously, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served in business development, communications and corporate legal capacities. Prior to his tenure with Lexicon Pharmaceuticals, Inc., Mr. Brady was a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co., LLC, and an associate in the New York and San Francisco offices of Morrison & Foerster LLP. Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from the New York University School of Law.

About 3-V Biosciences

3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel therapeutics that target host cell factors required for infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches. The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information


Merdad V. Parsey, MD, PhD

Chief Executive Officer

650-561-8600



SOURCE 3-V Biosciences, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES